ACADIA director exercises RSUs, gets new equity grants
ACADIA PHARMACEUTICALS director Elizabeth A. Garofalo reported equity compensation activity centered on RSUs and stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ACADIA PHARMACEUTICALS director Elizabeth A. Garofalo reported equity compensation activity centered on RSUs and stock options. On May 29, 2026, she exercised 8,107 restricted stock units into 8,107 shares of common stock, bringing her direct common stock holdings to 33,489 shares.
She also received a new grant of 9,311 restricted stock units, each representing one future share of common stock, and 16,004 director stock options with a strike price of $21.66 per share that vest quarterly over one year. The new RSUs will vest in full on the earlier of one year from grant or the next annual meeting, and she has elected to defer receipt of the underlying shares until specified future triggers.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 8,107 | $0.00 | $0.00 |
| Grant/Award | Director Stock Options (Right to Buy) | 16,004 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units | 9,311 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,107 | $0.00 | $0.00 |
Footnotes (4)
- F1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
- F2. The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
- F3. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
- F4. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
Key Figures
Key Terms
Restricted Stock Units financial
Director Stock Options financial
change in control financial
2024 Equity Incentive Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ACAD (ACADIA PHARMACEUTICALS) director Elizabeth Garofalo report in this Form 4?
What restricted stock unit awards did ACAD director Garofalo receive on May 29, 2026?
What are the terms of Elizabeth Garofalo’s new ACAD director stock options?
How were previously granted ACAD restricted stock units treated in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.